Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33151970" target="_blank" >RIV/61989592:15110/14:33151970 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects

Popis výsledku v původním jazyce

Fibroblast growth factor 21 (FGF 21) has been suggested as an independent factor for the protection of cardiovascular systém cells. We performed an anylasis to evaluate a possible association of FGF 21 levels with endothelial/hemostatik markers in asymptomati dyslipidemic individuals. We hypothesized that a potential protective actioncould be reflected in plasma elevationof FGF 21 in patients with adverse dyslipidemi phenotype. The study was conducted with asymptomatic patients (n=214), wubsequently divided into two groups (control group /CG/, n=66, 38 males, 28 females; dyslipidemic group /DLP/, n=148, 70 males, 78 females), according to apolipoprotein B (Apo B) and triglyceride levels. The plasma FGF 21 levels were measured by ELISA, while biochemical and endothelial/hemostatik markers were analysed by routine kit methods. In DLP (i.e. individuals with TG ? 1,5 mmol/l and/or apo B ? 1,2 g/l), plasma fibrinogen and FGF 21 levels were significantly higher (p { 0,01 and p { 0,001) compa

Název v anglickém jazyce

Fibroblast growth factor 21 and endothelial/hemostatic markers in dyslipidemic subjects

Popis výsledku anglicky

Fibroblast growth factor 21 (FGF 21) has been suggested as an independent factor for the protection of cardiovascular systém cells. We performed an anylasis to evaluate a possible association of FGF 21 levels with endothelial/hemostatik markers in asymptomati dyslipidemic individuals. We hypothesized that a potential protective actioncould be reflected in plasma elevationof FGF 21 in patients with adverse dyslipidemi phenotype. The study was conducted with asymptomatic patients (n=214), wubsequently divided into two groups (control group /CG/, n=66, 38 males, 28 females; dyslipidemic group /DLP/, n=148, 70 males, 78 females), according to apolipoprotein B (Apo B) and triglyceride levels. The plasma FGF 21 levels were measured by ELISA, while biochemical and endothelial/hemostatik markers were analysed by routine kit methods. In DLP (i.e. individuals with TG ? 1,5 mmol/l and/or apo B ? 1,2 g/l), plasma fibrinogen and FGF 21 levels were significantly higher (p { 0,01 and p { 0,001) compa

Druh

O - Ostatní výsledky

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů